AstraZeneca PLC Financials
| ZEG Stock | EUR 128.30 0.85 0.66% |
AstraZeneca |
Understanding current and past AstraZeneca PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AstraZeneca PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in AstraZeneca PLC's assets may result in an increase in income on the income statement.
AstraZeneca PLC Stock Summary
AstraZeneca PLC competes with Eli Lilly, AbbVie, Pfizer, Superior Plus, and Origin Agritech. AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. AstraZeneca PLC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 64400 people.| Foreign Associate | Germany |
| Instrument | Germany Stock View All |
| Exchange | Frankfurt Exchange |
| ISIN | GB0009895292 |
| Business Address | 1 Francis Crick |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | www.astrazeneca.com |
| Phone | 44 20 3749 5000 |
| Currency | EUR - Euro |
You should never invest in AstraZeneca PLC without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of AstraZeneca Stock, because this is throwing your money away. Analyzing the key information contained in AstraZeneca PLC's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
AstraZeneca PLC Key Financial Ratios
There are many critical financial ratios that AstraZeneca PLC's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that AstraZeneca PLC reports annually and quarterly.| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0555 | |||
| Beta | 0.19 | |||
| Z Score | 4.8 | |||
| Last Dividend Paid | 2.9 |
AstraZeneca Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AstraZeneca PLC's current stock value. Our valuation model uses many indicators to compare AstraZeneca PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AstraZeneca PLC competition to find correlations between indicators driving AstraZeneca PLC's intrinsic value. More Info.AstraZeneca PLC is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers reporting about 0.64 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for AstraZeneca PLC is roughly 1.55 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AstraZeneca PLC's earnings, one of the primary drivers of an investment's value.AstraZeneca PLC Systematic Risk
AstraZeneca PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AstraZeneca PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on AstraZeneca PLC correlated with the market. If Beta is less than 0 AstraZeneca PLC generally moves in the opposite direction as compared to the market. If AstraZeneca PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AstraZeneca PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AstraZeneca PLC is generally in the same direction as the market. If Beta > 1 AstraZeneca PLC moves generally in the same direction as, but more than the movement of the benchmark.
AstraZeneca PLC December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of AstraZeneca PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AstraZeneca PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of AstraZeneca PLC based on widely used predictive technical indicators. In general, we focus on analyzing AstraZeneca Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AstraZeneca PLC's daily price indicators and compare them against related drivers.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 12.38 | |||
| Value At Risk | (3.91) | |||
| Potential Upside | 2.15 |
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |